StreetAlpha.app
Home › Stocks › ACHV

Achieve Life Sciences, Inc. (ACHV)

Healthcare
$6.78
▲ +0.89%
LAST CLOSE · NOV 9

Achieve Life Sciences develops cytisinicline, a drug candidate intended to help people quit smoking or vaping. It last closed at $6.78 on Nov 9, up 0.89% on the day.

AI Auto Pilots
Is ACHV in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Net income
−$111.7M
EPS (diluted)
−$1.41
Valuation
Market cap
$746.0M
110.0M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$59.7M
At Sep 30
Shareholder equity
$180.7M
Shares outstanding
110.0M
At Nov 10
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$33.2M−$33.2MFY2021FY2022: −$42.4M−$42.4MFY2022FY2023: −$29.8M−$29.8MFY2023FY2024: −$39.8M−$39.8MFY2024FY2025: −$54.6M−$54.6MFY2025

From ACHV's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 10). Last 12 months adds up the four latest quarters.

Last report
Nov 10
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
1 Buy
1 firm · not enough for a consensus
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Ratings · 90 days
1 Buy
1firm
1 Buy0 Hold0 Sell
Only 1 firm rated ACHV in the past 90 days, not enough for a consensus
Average 12-month target
$18.00
▲ 165.5% upside

Based on 1 analyst who set a price target on ACHV in the past 90 days. The average target is $18.00, with a high of $18.00 and a low of $18.00, compared with the last close of $6.78.

Low $18.00Avg $18.00High $18.00
Blue marker: last close $6.78
Highest target$18.00
Average target$18.00
Lowest target$18.00
Latest rating changes
StifelInitiated
Sep 30Buy$18
Morgan StanleyInitiated
Aug 13Buy$13
HC Wainwright & Co.Reiterated
Jun 22Buy$12
Canaccord GenuityInitiated
Apr 21Buy$13
DateFirmActionRatingPrice target
Sep 30StifelInitiatedBuy$18
Aug 13Morgan StanleyInitiatedBuy$13
Jun 22HC Wainwright & Co.ReiteratedBuy$12
Apr 21Canaccord GenuityInitiatedBuy$13
Loading…

Technical Analysis

ACHV · as of the Nov 9 close · updated after every close
Pullback inside a longer uptrend

The stock sits between its 20 and 50 day averages. It is 16% above its 200 day average, so the longer trend is still up. Momentum is improving (RSI 48). The nearest support is the Pivot at $6.74, and the nearest resistance the Pivot R1 at $6.95.

Short trendBearish
Long trendBullish
MomentumImproving
StretchNormal
VolatilityNormal, 6.4%/day
Key levels
$8.6452 week high+27.4%
$7.2850 day average+7.4%
$7.11Swing high (Jul 1)+4.9%
$6.95100 day average+2.5%
$6.95Pivot R1+2.5%
$6.78Last close
$6.74Pivot−0.6%
$6.7320 day average−0.7%
$6.56Pivot S1−3.2%
$6.33Swing low (Oct 22)−6.6%
$5.67200 day average−16.4%
$2.6252 week low−61.4%
Indicators
RSI (14)47.93Middle of its rangeNeutral
MACD-0.14Above its signal lineBullish
Stochastic36.0Middle of its rangeNeutral
ADX (14)17.9No clear trend
Williams %R-49.0Oversold below −80, overbought above −20Neutral
CCI (20)2.1Oversold below −100, overbought above 100Neutral
Rate of change+3.7%Change over 10 sessionsBullish
ATR (14)$0.43Typical daily range, 6.4% of price
MA 10Below
MA 20Above
MA 50Below
MA 100Below
MA 200Above
What happened before, for ACHV

What happened before

See how ACHV did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow ACHV usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How ACHV has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2006.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D

No whale options trades in ACHV in the last 90 days.

Loading…

See today’s whale options flow across the market →

ACHV Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲76 buying vs 37 selling
  • ▲Held by funds +11.4 pts
  • ▲Funds holding +20
  • ▲Superinvestors: 3 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding132112+17.9%
In funds' top 10220.0%
Held by funds86.5%75.2%+11.4 pts
New / increased33 / 4347 / 36−8.4%
Reduced / sold out24 / 1315 / 17+15.6%
Put/call ratio0.000.00−100.0%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ACHV institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ACHV is in one of them and how their past ACHV trades turned out.

ACHV in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ACHV in an article yet. Here's the latest on the wider market.

About Achieve Life Sciences

Achieve Life Sciences is a specialty pharmaceutical company based in Seattle, Washington. It is developing cytisinicline, a drug candidate for treating nicotine dependence in people who want to quit smoking or vaping. The drug has not yet been approved by U.S. regulators. Its target customers are adult smokers and vapers, and the company also holds rights to commercialize the drug in regions outside a European partner's territory.

Headquarters
Seattle, WA